Skip to main content
Top
Published in: Calcified Tissue International 1/2012

01-01-2012 | Original Research

Vitamin K2 Improves Renal Function and Increases Femoral Bone Strength in Rats with Renal Insufficiency

Authors: Jun Iwamoto, Azusa Seki, Yoshihiro Sato, Hideo Matsumoto

Published in: Calcified Tissue International | Issue 1/2012

Login to get access

Abstract

Renal insufficiency induces cortical bone loss in rats. The present study examined the influence of vitamin K2 on renal function, cortical bone mass, and bone strength in rats with renal insufficiency. Thirty male Sprague-Dawley rats (8 weeks old) were randomized by the stratified weight method to the following three groups of 10 animals each: sham operation (control), 5/6 nephrectomy, and 5/6 nephrectomy + oral vitamin K2 (menaquinone-4, menatetrenone, 30 mg/kg, 5 days/week). Treatment was initiated 10 days after surgery. After 6 weeks of treatment, samples of serum, urine, and bone (femur and tibia) were obtained. Renal function was evaluated, bone histomorphometric analysis was performed on the tibial diaphysis, and the bone mineral density (BMD) and mechanical strength of the femoral diaphysis were determined by peripheral quantitative computed tomography and a three-point bending test, respectively. Nephrectomy induced renal dysfunction, as indicated by increased levels of serum creatinine and urea nitrogen along with a decrease of creatinine clearance; and it also decreased BMD without significantly affecting bone strength at the femoral diaphysis. Vitamin K2 improved renal function parameters but did not significantly influence BMD at the femoral diaphysis. However, vitamin K2 decreased the bone marrow area of the tibial diaphysis and increased the stiffness of the femoral diaphysis. These findings suggest that administration of vitamin K2 improves renal function and increases cortical bone strength without altering BMD in rats with renal insufficiency.
Literature
1.
go back to reference Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18:282–286PubMedCrossRef Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18:282–286PubMedCrossRef
2.
go back to reference Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223–3232PubMedCrossRef Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223–3232PubMedCrossRef
3.
go back to reference Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731PubMedCrossRef Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721–731PubMedCrossRef
4.
go back to reference West SL, Lok CE, Jamal SA (2010) Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World Environments (FRACTURE): a prospective study. BMC Nephrol 11:17PubMedCrossRef West SL, Lok CE, Jamal SA (2010) Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World Environments (FRACTURE): a prospective study. BMC Nephrol 11:17PubMedCrossRef
5.
go back to reference Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA (2010) Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis. Nephron Clin Pract 116:c256–c262PubMedCrossRef Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA (2010) Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis. Nephron Clin Pract 116:c256–c262PubMedCrossRef
6.
go back to reference Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67:876–881PubMedCrossRef Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67:876–881PubMedCrossRef
7.
go back to reference Jamal SA, Gilbert J, Gordon C, Bauer DC (2006) Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21:543–548PubMedCrossRef Jamal SA, Gilbert J, Gordon C, Bauer DC (2006) Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21:543–548PubMedCrossRef
8.
go back to reference Jamal SA, Leiter RE, Jassal V, Hamilton CJ, Bauer DC (2006) Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos Int 17:1390–1397PubMedCrossRef Jamal SA, Leiter RE, Jassal V, Hamilton CJ, Bauer DC (2006) Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos Int 17:1390–1397PubMedCrossRef
10.
go back to reference Lindberg JS, Moe SM (1999) Osteoporosis in end-state renal disease. Semin Nephrol 19:115–122PubMed Lindberg JS, Moe SM (1999) Osteoporosis in end-state renal disease. Semin Nephrol 19:115–122PubMed
11.
go back to reference Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190PubMedCrossRef Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186–190PubMedCrossRef
12.
go back to reference Iwamoto J, Matsumoto H, Takeda T (2009) Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Clin Drug Investig 29:471–479PubMedCrossRef Iwamoto J, Matsumoto H, Takeda T (2009) Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials. Clin Drug Investig 29:471–479PubMedCrossRef
13.
go back to reference Cockyne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256–1261CrossRef Cockyne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256–1261CrossRef
14.
go back to reference Hauschka PV, Lian JB, Cole DEC, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed Hauschka PV, Lian JB, Cole DEC, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed
16.
go back to reference Vermeer C, Jie KSG, Knapen MHJ (1995) Role of vitamin K in bone metabolism. Annu Rev Nutr 15:1–22PubMedCrossRef Vermeer C, Jie KSG, Knapen MHJ (1995) Role of vitamin K in bone metabolism. Annu Rev Nutr 15:1–22PubMedCrossRef
17.
go back to reference Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B (2003) Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919–43927PubMedCrossRef Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B (2003) Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919–43927PubMedCrossRef
18.
go back to reference Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL (2010) Vitamins K and D status in stages 3–5 chronic kidney disease. Clin J Am Soc Nephrol 5:590–597PubMedCrossRef Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL (2010) Vitamins K and D status in stages 3–5 chronic kidney disease. Clin J Am Soc Nephrol 5:590–597PubMedCrossRef
19.
go back to reference Luukinen H, Käkönen SM, Pettersson K, Koski K, Laippala P, Lövgren T, Kivelä SL, Väänänen HK (2000) Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15:2473–2478PubMedCrossRef Luukinen H, Käkönen SM, Pettersson K, Koski K, Laippala P, Lövgren T, Kivelä SL, Väänänen HK (2000) Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15:2473–2478PubMedCrossRef
20.
go back to reference Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82:719–724PubMedCrossRef Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82:719–724PubMedCrossRef
21.
go back to reference Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 18:487–488PubMedCrossRef Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 18:487–488PubMedCrossRef
22.
go back to reference Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:1769–1774PubMedCrossRef Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:1769–1774PubMedCrossRef
23.
go back to reference Jokihaara J, Järvinen TL, Jolma P, Kööbi P, Kalliovalkama J, Tuukkanen J, Saha H, Sievänen H, Kannus P, Pörsti I (2006) Renal insufficiency-induced bone loss is associated with an increase in bone size and preservation of strength in rat proximal femur. Bone 39:353–360PubMedCrossRef Jokihaara J, Järvinen TL, Jolma P, Kööbi P, Kalliovalkama J, Tuukkanen J, Saha H, Sievänen H, Kannus P, Pörsti I (2006) Renal insufficiency-induced bone loss is associated with an increase in bone size and preservation of strength in rat proximal femur. Bone 39:353–360PubMedCrossRef
24.
go back to reference Miller MA, Chin J, Miller SC, Fox J (1998) Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23:257–266PubMedCrossRef Miller MA, Chin J, Miller SC, Fox J (1998) Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23:257–266PubMedCrossRef
25.
go back to reference Berger I, Piecha G, Rabkin R, Kaya N, Geldyyev A, Sun D, Chen Y, Koleganova N, Gross ML (2007) Growth hormone treatment prevents osteoporosis in uremic rats. Histol Histopathol 22:1231–1239PubMed Berger I, Piecha G, Rabkin R, Kaya N, Geldyyev A, Sun D, Chen Y, Koleganova N, Gross ML (2007) Growth hormone treatment prevents osteoporosis in uremic rats. Histol Histopathol 22:1231–1239PubMed
26.
go back to reference Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M (2005) Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 20:1904–1911PubMedCrossRef Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M (2005) Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 20:1904–1911PubMedCrossRef
27.
go back to reference Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2011) Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48:1260–1267PubMedCrossRef Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2011) Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48:1260–1267PubMedCrossRef
28.
go back to reference Iwamoto J, Seki A, Sato Y, Matsumoto H, Tadeda T, Yeh JK (2010) Vitamin K2 promotes bone healing in a rat femoral osteotomy model with or without glucocorticoid treatment. Calcif Tissue Int 86:234–241PubMedCrossRef Iwamoto J, Seki A, Sato Y, Matsumoto H, Tadeda T, Yeh JK (2010) Vitamin K2 promotes bone healing in a rat femoral osteotomy model with or without glucocorticoid treatment. Calcif Tissue Int 86:234–241PubMedCrossRef
29.
go back to reference Iwamoto J, Yeh JK, Schmidt A, Rowley E, Stanfield L, Takeda T, Sato M (2005) Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats. Calcif Tissue Int 77:119–126PubMedCrossRef Iwamoto J, Yeh JK, Schmidt A, Rowley E, Stanfield L, Takeda T, Sato M (2005) Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats. Calcif Tissue Int 77:119–126PubMedCrossRef
30.
go back to reference Villanueva AR (1974) A bone stain for osteoid seams in fresh, unembedded, mineralized bone. Stain Technol 49:1–8PubMed Villanueva AR (1974) A bone stain for osteoid seams in fresh, unembedded, mineralized bone. Stain Technol 49:1–8PubMed
31.
go back to reference Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef
32.
go back to reference Chen MM, Yeh JK, Aloia JF, Tierney JM, Sprintz S (1994) Effect of treadmill exercise on tibial cortical bone in aged female rats: a histomorphometry and dual energy X-ray absorptiometry study. Bone 15:313–319PubMedCrossRef Chen MM, Yeh JK, Aloia JF, Tierney JM, Sprintz S (1994) Effect of treadmill exercise on tibial cortical bone in aged female rats: a histomorphometry and dual energy X-ray absorptiometry study. Bone 15:313–319PubMedCrossRef
33.
go back to reference Iwamoto J, Matsumoto H, Takeda T, Sato Y, Liu X, Yeh JK (2008) Effects of vitamin K2 and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int 83:121–128PubMedCrossRef Iwamoto J, Matsumoto H, Takeda T, Sato Y, Liu X, Yeh JK (2008) Effects of vitamin K2 and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int 83:121–128PubMedCrossRef
34.
go back to reference Iwamoto J, Matsumoto H, Takeda T, Sato Y, Yeh JK (2010) Effects of vitamin K2 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats. Calcif Tissue Int 87:254–262PubMedCrossRef Iwamoto J, Matsumoto H, Takeda T, Sato Y, Yeh JK (2010) Effects of vitamin K2 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats. Calcif Tissue Int 87:254–262PubMedCrossRef
35.
go back to reference Tamura K, Suzuki Y, Matsushita M, Fujii H, Miyaura C, Aizawa S, Kogo H (2007) Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 558:159–166PubMedCrossRef Tamura K, Suzuki Y, Matsushita M, Fujii H, Miyaura C, Aizawa S, Kogo H (2007) Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 558:159–166PubMedCrossRef
36.
go back to reference Mandalunis P, Ubios A (2005) Experimental renal failure and iron overload: a histomorphometric study in rat tibia. Toxicol Pathol 33:398–403PubMedCrossRef Mandalunis P, Ubios A (2005) Experimental renal failure and iron overload: a histomorphometric study in rat tibia. Toxicol Pathol 33:398–403PubMedCrossRef
37.
go back to reference Schrooten I, Behets GJ, Cabrera WE, Vercauteren SR, Lamberts LV, Verberckmoes SC, Bervoets AJ, Dams G, Goodman WG, De Broe ME, D’Haese PC (2003) Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int 63:927–935PubMedCrossRef Schrooten I, Behets GJ, Cabrera WE, Vercauteren SR, Lamberts LV, Verberckmoes SC, Bervoets AJ, Dams G, Goodman WG, De Broe ME, D’Haese PC (2003) Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int 63:927–935PubMedCrossRef
38.
go back to reference Nazarian A, Cory E, Müller R, Snyder BD (2009) Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. Osteoporos Int 20:123–132PubMedCrossRef Nazarian A, Cory E, Müller R, Snyder BD (2009) Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. Osteoporos Int 20:123–132PubMedCrossRef
39.
go back to reference Hopper TA, Wehrli FW, Saha PK, Andre JB, Wright AC, Sanchez CP, Leonard MB (2007) Quantitative microcomputed tomography assessment of intratrabecular, intertrabecular, and cortical bone architecture in a rat model of severe renal osteodystrophy. J Comput Assist Tomogr 31:320–328PubMedCrossRef Hopper TA, Wehrli FW, Saha PK, Andre JB, Wright AC, Sanchez CP, Leonard MB (2007) Quantitative microcomputed tomography assessment of intratrabecular, intertrabecular, and cortical bone architecture in a rat model of severe renal osteodystrophy. J Comput Assist Tomogr 31:320–328PubMedCrossRef
40.
go back to reference Fusaro M, Crepaldi G, Maggi S, Galli F, D’Angelo A, Calò L, Giannini S, Miozzo D, Gallieni M (2011) Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J Endocrinol Invest 34:317–323PubMed Fusaro M, Crepaldi G, Maggi S, Galli F, D’Angelo A, Calò L, Giannini S, Miozzo D, Gallieni M (2011) Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J Endocrinol Invest 34:317–323PubMed
41.
go back to reference Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA (2010) The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 5:568–575PubMedCrossRef Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA (2010) The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 5:568–575PubMedCrossRef
42.
go back to reference Worcester EM, Sebastian JL, Hiatt JG, Beshensky AM, Sadowski JA (1993) The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int 53:242–248PubMedCrossRef Worcester EM, Sebastian JL, Hiatt JG, Beshensky AM, Sadowski JA (1993) The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int 53:242–248PubMedCrossRef
43.
go back to reference Nakagawa Y (1997) Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Keio J Med 46:1–9PubMedCrossRef Nakagawa Y (1997) Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Keio J Med 46:1–9PubMedCrossRef
44.
go back to reference Ochiai M, Nakashima A, Takasugi N, Kiribayashi K, Kawai T, Usui K, Shigemoto K, Hamaguchi N, Kohno N, Yorioka N (2011) Vitamin K2 alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract 117:c15–c19PubMedCrossRef Ochiai M, Nakashima A, Takasugi N, Kiribayashi K, Kawai T, Usui K, Shigemoto K, Hamaguchi N, Kohno N, Yorioka N (2011) Vitamin K2 alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract 117:c15–c19PubMedCrossRef
45.
go back to reference Ferretti JL, Capozza RF, Zanchetta JR (1996) Mechanical validation of a tomographic (pQCT) index for noninvasive estimation of rat femur bending strength. Bone 18:97–102PubMedCrossRef Ferretti JL, Capozza RF, Zanchetta JR (1996) Mechanical validation of a tomographic (pQCT) index for noninvasive estimation of rat femur bending strength. Bone 18:97–102PubMedCrossRef
46.
go back to reference Iwamoto J, Sato Y, Takeda T, Matsumoto H (2011) Bone quality and vitamin K2 in type 2 diabetes: review of preclinical and clinical studies. Nutr Rev 69:162–167PubMedCrossRef Iwamoto J, Sato Y, Takeda T, Matsumoto H (2011) Bone quality and vitamin K2 in type 2 diabetes: review of preclinical and clinical studies. Nutr Rev 69:162–167PubMedCrossRef
47.
go back to reference Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T (2002) A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 71:69–79PubMedCrossRef Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T (2002) A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 71:69–79PubMedCrossRef
48.
go back to reference Kobayashi M, Hara K, Akiyama Y (2004) Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet. Bone 35:1136–1143PubMedCrossRef Kobayashi M, Hara K, Akiyama Y (2004) Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet. Bone 35:1136–1143PubMedCrossRef
49.
go back to reference Saito M, Fujii K, Soshi S (2005) Effects of vitamin B6 and vitamin K2 on bone mechanical properties and collagen cross-links in spontaneously diabetic WBN/Kob rats. J Bone Miner Res 20(suppl 1):S286 Saito M, Fujii K, Soshi S (2005) Effects of vitamin B6 and vitamin K2 on bone mechanical properties and collagen cross-links in spontaneously diabetic WBN/Kob rats. J Bone Miner Res 20(suppl 1):S286
50.
go back to reference Saito M (2009) Vitamin K2 and bone quality [in Japanese]. J Osteoporotic Med 8:205–211 Saito M (2009) Vitamin K2 and bone quality [in Japanese]. J Osteoporotic Med 8:205–211
51.
go back to reference Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G (1998) Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23:187–196PubMedCrossRef Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G (1998) Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23:187–196PubMedCrossRef
52.
go back to reference Tanaka S, Narusawa K, Onishi H, Miura M, Hijioka A, Kanazawa Y, Nishida S, Ikeda S, Nakamura T (2011) Lower osteocalcin and osteopontin contents of the femoral head in hip fracture patients than osteoarthritis patients. Osteoporos Int 22:587–597PubMedCrossRef Tanaka S, Narusawa K, Onishi H, Miura M, Hijioka A, Kanazawa Y, Nishida S, Ikeda S, Nakamura T (2011) Lower osteocalcin and osteopontin contents of the femoral head in hip fracture patients than osteoarthritis patients. Osteoporos Int 22:587–597PubMedCrossRef
Metadata
Title
Vitamin K2 Improves Renal Function and Increases Femoral Bone Strength in Rats with Renal Insufficiency
Authors
Jun Iwamoto
Azusa Seki
Yoshihiro Sato
Hideo Matsumoto
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2012
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-011-9548-3

Other articles of this Issue 1/2012

Calcified Tissue International 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.